Evidence map›Paper›PMID 30358840›Full record

ArticleInternational journal of epidemiology2019

HIV testing and counselling couples together for affordable HIV prevention in Africa.

Kristin M Wall, Mubiana Inambao, William Kilembe, Etienne Karita, Bellington Vwalika, Joseph Mulenga, Rachel Parker, Tyronza Sharkey, Divya Sonti, Amanda Tichacek and 6 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in International journal of epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Psychosocial support for HIV serodiscordant couples.Health psychology and behavioral medicine · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Kristin M WallRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Mubiana InambaoRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
William KilembeRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Etienne KaritaRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Bellington VwalikaRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Joseph MulengaRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Rachel ParkerRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Tyronza SharkeyRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Divya SontiRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Amanda TichacekRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Eric HunterRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Robert YohnkaRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Joseph F AbdallahRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Ibou ThiorArise Program.
Julie PulerwitzArise Program, HIV/AIDS and TB Global Program, PATH, Washington, DC, USA.
Susan AllenRwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School.
Rwanda Zambia HIV Research Group · RWArise · BEEmory University · USProgram for Appropriate Technology in Health · USUniversity of Zambia · ZM

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Virologic Correlates of Heterosexual TransmissionR01AI051231 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, TODD M, HUNTER, ERIC · 2002 to 2022
$9.9M
EMORY AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW001042 · FIC · EMORY UNIVERSITY · PI DEL RIO, CARLOS · 1998 to 2013
$6.8M
Couples HIV Counseling &Testing in two African capitalsR01MH066767 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, SUSAN A · 2002 to 2006
$6.1M
Family Planning Promotion in HIV Infected ZambiansR01HD040125 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, SUSAN A. · 2001 to 2005
$4.2M
VCT with Primary and Concurrent Partners to Prevent HIV Transmission R01MH095503 · NIMH · EMORY UNIVERSITY · PI ALLEN, SUSAN A · 2011 to 2016
$2.5M
Improving allocation of limited HIV prevention and treatment resources in ZambiaK01MH107320 · NIMH · EMORY UNIVERSITY · PI WALL, KRISTIN MARIE · 2016 to 2019
$515k
FIC NIH HHS D43 TW001042NCHHSTP CDC HHS U2G PS000758NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI051231NICHD NIH HHS R01 HD040125NIH HHS P51 OD011132NIMH NIH HHS K01 MH107320NIMH NIH HHS R01 MH066767NIMH NIH HHS R01 MH095503
6 · The paper itself

Abstract

backgroundThe impact and cost-effectiveness of couples' voluntary HIV counselling and testing (CVCT) has not been quantified in real-world settings. We quantify cost-per-HIV-infection averted by CVCT in Zambia from the donor's perspective.

methodsFrom 2010 to 2016, CVCT was established in 73 Zambian government clinics. The cost-per-HIV-infection averted (CHIA) of CVCT was calculated using observed expenditures and effectiveness over longitudinal follow-up. These observed measures parameterized hypothetical 5-year nationwide implementations of: 'CVCT'; 'treatment-as-prevention (TasP) for discordant couples' identified by CVCT; and 'population TasP' for all HIV+ cohabiting persons identified by individual testing.

resultsIn all, 207 428 couples were tested (US $52/couple). Among discordant couples in which HIV+ partners self-reported antiretroviral therapy (ART), HIV incidence was 8.5/100 person-years before and 1.8/100 person-years after CVCT (79% reduction). Corresponding reductions for non-ART-using discordant and concordant negative couples were 63% and 47%, respectively. CVCT averted an estimated 58% of new infections at US $659 CHIA. In nationwide implementation models, CVCT would prevent 17 times the number of infections vs 'TasP for discordant couples' at 86% of the cost, and nine times the infections vs 'population TasP' at 28% of the cost.

conclusionsCVCT is a cost-effective, feasible prevention strategy in Zambia. We demonstrate the novel, added effectiveness of providing CVCT to ART users, for whom ART use alone only partially mitigated transmission risk. Our results indicate a major policy shift (supporting development of CVCT indicators, budgets and targets) and have clinical implications (suggesting promotion of CVCT in ART clinics as a high-impact prevention strategy).

Indexed as

Sexual PartnersAdultAnti-Retroviral AgentsCosts and Cost AnalysisCounselingFemaleHIV InfectionsHumansMaleMass ScreeningProgram EvaluationVoluntary ProgramsZambiaAnti-Retroviral Agentscost-per-HIV-infection avertedCouples’financial cost-effectivenessHIV preventiontreatment-as-preventionvoluntary HIV counselling and testing

Identifiers

PMID30358840
PMCPMC6380312
OpenAlexW2898362767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.